[1] MIMAMI K. Recent evidences in the pharmacological mechanisms of the tramadol. Mazui，2005，54（11）：1224-1233.

[2] TERLINDEN R，OSSIG J，FLIEGERT F，et al. Absorption，metabolism，and excretion of ¹⁴C-labeled Tapentadol HCl in healthy male subjects. Eur J Drug Metab Pharmacokinet，2007，32（3）：163-169.

[3] TERLINDEN R，KOGEL B Y，ENGLBERGER W，et al. In vitro and in vivo characterization of tapentadol metabolites. Methods Find Exp Clin Pharmacol，2010，32（1）：31-38.

[4] REIG E. Tramadol in musculoskeletal pain - a survey. Clin Rheumatol，2002，21 Suppl 1：S9-11；discussion S11-12.

[5] HERRERA S J. The use of oral opioids in neuropathic pain：development of new tramadol and morphine formulations. Revista de la Sociedad Espanola der Dolor，2001，8：32-34.

[6] APAYDIN S，UYARM，KARABAY N U，et al. The antinociceptive effect of tramadol on a model of neuropathic pain in rats. Life Sci，2000，66（17）：1627-1637.

[7] HOLLINGSHEAD J，DUHMKE R M，CORNBLATH D R. Tramadol for neuropathic pain. Cochrane Database Syst Rev，2006，19（3）：CD003726.

[8] DANIELS S E，UPMALIS D，OKAMOTO A，et al. A randomized，double-blind，phase Ⅲ study comparing multiple doses of tapentadol IR，oxycodone IR，and placebo for postoperative（bunionectomy）pain. Curr Med Res Opin，2009，25（3）：765-776.

[9] AFILALO M. Efficacy of tapentadol ER for managing moderate to severe chronic pain. Pain Physician，2013，16（1）：27-40.

[10] ETROPOLSKI M，KUPERWASSER B，FLÜGEL M，et al. Safety and tolerability of tapentadol extended release in moderate to severe chronic osteoarthritis or low back pain management：pooled analysis of randomized controlled trials. Adv Ther，2014，31（6）：604-620.